3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Ovarian Neoplasms
69
Fallopian Tube Neoplasms
18
Endometrial Neoplasms
8
Carcinoma, Ovarian Epithelial
8
Breast Neoplasms
7
Neoplasms
5
Pancreatic Neoplasms
3
Cystadenocarcinoma, Serous
3
Uterine Neoplasms
2
Uterine Cervical Neoplasms
2
Urogenital Neoplasms
2
Prostatic Neoplasms
2
Ovarian Diseases
2
Neoplasm Metastasis
2
Gonadal Disorders
2
Genital Neoplasms, Female
2
Genital Diseases, Female
2
Endocrine System Diseases
2
Endocrine Gland Neoplasms
2
Carcinoma
2
Adnexal Diseases
2
Urologic Neoplasms
1
Triple Negative Breast Neoplasms
1
Thrombocytopenia
1
Sarcoma
1
Recurrent/ Advanced Stage Endometrial Cancer Patients
1
Recurrence
1
Prostatic Diseases
1
Platinum-resistant Recurrent Clear Cell Ovarian Cancer
1
Platinum-resistant Ovarian Cancer
1
Interventions
anlotinib
2
Ocoxin
2
Bevacizumab
2
pembrolizumab
1
olaparib
1
niraparib
1
lenvatinib
1
catumaxomab
1
Papanicolaou Test
1
Paclitaxel
1
Human Papillomavirus DNA Tests
1
Filgrastim
1
Drug Therapy
1
Colposcopy
1
Cell Count
1
Carboplatin
1
CP protocol
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms, Glandular and Epithelial
×
niraparib
×
Gynecologic
×
Clear all
NCT04556071
2020-11-10
AVANIRA3
Jiangsu Cancer Institute & Hospital
Phase 2
Unknown
32 enrolled